Company profile
Organogenesis Holdings Inc.
NASDAQ: ORGO · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Canton, MACIK 0001661181Reports USD
#204 of 1,418 Healthcare companies by revenue63rd-percentile growth
EA Score
65BFH 74DQ 61GM 48SS 67
v0.1 · 65/100 weight · provisional
↑ return on assets, return on equity · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$513.6M
Rev growth YoY (TTM)
+11.9%
Net income (FY)
$37.0M
Employees
854
as of 2026-08-13
Market cap
$232.9M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$564.2M$564.2M2025
Net income$37.0M$37.0M2025
Operating income$44.7M$44.7M2025
Total assets$598.7M$598.7M2025
Liabilities$164.8M$164.8M2025
Equity$300.1M$300.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
Grant0%
By geography
Not disclosed.
The read
What is Organogenesis Holdings Inc.’s revenue?
Organogenesis Holdings Inc. booked $564.2M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a 6.6% net margin.
Peers · Healthcare
Catalyst Pharmaceuticals, Inc.83B+Hinge Health, Inc.47DBioventus Inc.66BAtriCure, Inc.84B+Mirum Pharmaceuticals, Inc.64CVeracyte, Inc.82B+Key facts
CEOGary S. Gillheeney
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCanton, MA
ExchangeNASDAQ: ORGO
Employees854
IPO date2017-01-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.